Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

2.

De Novo Stage 4 Metastatic Breast Cancer: A Surgical Disease?

Barbie TU, Golshan M.

Ann Surg Oncol. 2018 Oct;25(11):3109-3111. doi: 10.1245/s10434-018-6664-6. Epub 2018 Jul 17. No abstract available.

PMID:
30019303
3.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

4.

Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.

Barbie TU, Ma C, Margenthaler JA.

Ann Surg Oncol. 2015 Nov;22(12):3861-5. doi: 10.1245/s10434-015-4487-2. Epub 2015 Mar 18.

PMID:
25783678
5.

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC, Barbie DA, Gillanders WE.

J Clin Invest. 2014 Dec;124(12):5411-23. doi: 10.1172/JCI75661. Epub 2014 Nov 3.

6.

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA.

Cancer Discov. 2014 Apr;4(4):452-65. doi: 10.1158/2159-8290.CD-13-0646. Epub 2014 Jan 20.

7.

Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6. Epub 2003 Dec 11.

Supplemental Content

Loading ...
Support Center